Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1547 results about "Suppressor cell" patented technology

Suppressor cells. Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia. cells of the immune system that inhibit or help to terminate an immune response, for example, suppressor macrophages and suppressor T cells.

Compositions and methods for inhibiting expression of coagulation factor xi (FXI)

PCT designated stage expiredWO2024240058A1Organic active ingredientsBlood disorderDiseaseNucleotide
Compositions and methods useful to inhibiting the expression of Plasma Coagulation Factor XI (FXI) gene and for treatment of FXI -associated diseases and conditions are provided. Provided are FXI dsRNA agents, FXI antisense polynucleotide agents, compositions comprising FXI dsRNA agents, and compositions comprising FXI antisense polynucleotide agents that can be used to inhibiting FXI expression in cells and subjects.
Owner:SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD

Pan-KRAS targeted protein degradation agent, preparation method therefor, and use thereof

The present invention provides a class of small molecule compounds for targeted degradation of a pan-KRAS protein, a preparation method therefor, and use thereof as a therapeutic agent for preventing and / or treating cancer. The compound of the present invention can effectively degrade and / or inhibit the pan-KRAS protein in cells, and can be used for preparing a drug for treating and / or preventing related diseases or disorders caused by pan-KRAS mediation.
Owner:LEADING PHARMACEUTICAL (SHAOXING) CO LTD

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

KRAS g12d degradation agent as well as preparation method therefor and use thereof

Disclosed in the present invention are a KRAS G12D degradation agent as well as a preparation method therefor and the use thereof. The present invention provides compounds as shown below, and / or stereoisomers, enantiomers, diastereoisomers, atropisomers, deuterated compounds, hydrates, solvates, prodrugs and / or pharmaceutically acceptable salts thereof. The compounds provided by the present invention can effectively degrade and / or inhibit KRAS G12D protein in cells, and can be used for preparing drugs for treating and / or preventing related diseases or disorders caused by KRAS G12D mediation. G-L-E I
Owner:LEADING PHARMACEUTICAL (SHAOXING) CO LTD

Application of sea cucumber-derived nano-vesicles in preparation of medicine for promoting wound repair

The invention relates to application of sea cucumber-derived nano-vesicles in preparation of a medicine for promoting wound repair. The nano-vesicles (SC-EVs) extracted and prepared from sea cucumbers can effectively promote cell migration, scratch repair and tube forming capabilities of human skin epithelial cells (HACAT) and human skin microvascular endothelial cells (HM DEC) and inhibit cell apoptosis, so that the capability of repairing cells is achieved, and particularly the effect of repairing wound surfaces in a high glucose state or diabetes mellitus is achieved. The invention provides a new direction and thought for the application of the sea cucumber-sourced nano vesicles (SC-EVs), provides a brand new drug research and development and clinical treatment direction for wound repair, especially for solving the problem of difficult healing of wounds of patients with high glucose or diabetes, and has extremely high social value and market application prospect.
Owner:JINAN UNIVERSITY

Copper complex with anticancer activity and preparation method and application thereof

The invention belongs to the field of anti-cancer metal complexes, and particularly relates to a copper complex with anti-cancer activity and a preparation method and application thereof. Cu (OAc) 2H2O and coumarin-3-formyl-(2-aminomethylpyridine) are respectively dissolved in a solvent, the two solutions are mixed and stirred at room temperature to react for a period of time, the reaction solution is filtered, the filtrate is sealed and naturally volatilized at room temperature for 3-7 days, the complex can be obtained, the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M, and the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M. According to the present invention, the inhibition effect of the complex on HeLa cervical cancer cells is 3.38 times of the inhibition effect of cis-platinum, the toxicity of the complex on normal cells but HUVEC is very small, IC50 is greater than 100 [mu] M, and the complex has a high selectivity coefficient SI (SI = normal cell IC50 / cancer cell IC50), and the selectivity coefficient SI is greater than 111 and is 584 times of the selectivity coefficient of cis-platinum (SI = 0.19). The complex has the capability of inducing apoptosis of cancer cells and has concentration dependence. Meanwhile, the complex can retard cancer cells and an S phase so as to inhibit cell proliferation, and can generate an intercalation effect with HS-DNA (High-Speed Deoxyribose Nucleic Acid).
Owner:NANJING FORESTRY UNIV

Engineered probiotics for radiosensitization and tumor metabolism regulation as well as preparation method and application of engineered probiotics

PendingCN120884611ABacteriaAntibody ingredientsImmunoradiometryT cell
The invention belongs to the technical field of engineered probiotics, and particularly relates to engineered probiotics for radiosensitization and tumor metabolism regulation as well as a preparation method and application of the engineered probiotics. The engineering probiotics comprise probiotics and core-shell type metal nanoparticles which are loaded on the probiotics and are synthesized through a biological directional mineralization effect; the core of the core-shell type metal nanoparticle is a palladium element, and the outer layer of the core-shell type metal nanoparticle is a palladium element and a gold element. The engineering probiotics provided by the invention have excellent enzyme catalysis performance and can target and retain in tumor sites, and through the synergistic effect of all components in the engineering probiotics, adenosine metabolism is effectively inhibited, secretion of pro-inflammatory cytokines is enhanced, tumor microenvironment is promoted to be converted into an inflammatory state, up-regulation of immune checkpoints is inhibited, and the immune checkpoints are inhibited. And T cells are inhibited from being transformed into depletion phenotype and transformed into effect type from depletion type. After the SBRT and the immune checkpoint inhibitor are combined for use, the growth of tumors can be effectively inhibited, and the effect of enhancing immune radiotherapy is achieved.
Owner:HUAZHONG UNIV OF SCI & TECH

Method for improving NK (Natural Killer) cell effect function through targeted lactic acid modification

The invention belongs to the technical field of immunotherapy, and particularly relates to a method for improving NK cell functions by targeted inhibition of lactylation. The invention provides a method for improving functions of NK cells by targeted inhibition of lactylation, NK cell lactic acid transporters or modification enzymes in inhibition of the lactylation process are targeted, the modification enzymes are NK cell lactylation modification enzymes Writer or lactic acid coenzyme A synthetase, NK92MI lactylation modification is blocked, so that function depletion of the NK cells is reversed, and the NK cell function is improved. The function of the NK cell can be partially reversed by inhibiting the lactic acid modification, and the expression level of effector molecules of the NK92MI cell can be recovered.
Owner:SHANDONG UNIV

Bird's nest peptide for promoting fibroin and inhibiting expression of inflammatory factors

The invention provides cubilose peptide derived from cubilose and capable of promoting silk polyprotein and inhibiting expression of inflammatory factors and application of the cubilose peptide. The amino acid sequence of the peptide is as shown in at least one of SEQ ID NO: 1-5. The peptide disclosed by the invention is derived from cubilose, has the performance advantages of being small in molecular weight, promoting the expression of cell filament protein, inhibiting the expression of cell inflammatory factors and reducing the level of reactive oxygen free radicals of cells, has the biological activity of moisturizing, resisting inflammation and resisting oxidation, can be used for preparing medicines, daily chemical products, moisturizing products, anti-oxidation products or anti-inflammatory products, and is wide in application prospect.
Owner:XIAMEN YAN PALACE SEELONG BIOTECHNOLOGY CO LTD

Culture medium and method for inhibiting cell aging through mesenchymal stem cell amplification

The invention belongs to the technical field of stem cells, and particularly relates to a culture medium and method for inhibiting cell aging through mesenchymal stem cell amplification, and the culture medium comprises a cAMP pathway activator and a bispecific tyrosine phosphorylation regulation kinase inhibitor. The invention provides a method for promoting in-vitro amplification of mesenchymal stem cells and inhibiting cell aging by using a cAMP pathway activator and a bispecific tyrosine phosphorylation regulation kinase inhibitor I NDY, after the MSC is subjected to nearly 15 generations of culture by adopting the culture medium disclosed by the invention, the surface labeled protein and the three-way differentiation function are normal, and compared with P10-generation MSC cells cultured by adopting a conventional culture medium, the surface labeled protein and the three-way differentiation function are normal. The indexes such as cell proliferation speed and cell aging are obviously improved.
Owner:GUOKE MINGYAO (SHANDONG) MEDICAL TECHNOLOGY CO LTD

Glutamic acid derivative as well as preparation method and application thereof in rhythm gene regulation and oxidation resistance

The invention relates to the technical field of oxidation resistance, in particular to a glutamic acid derivative, a preparation method thereof and application of the glutamic acid derivative in rhythm gene regulation and oxidation resistance. The glutamic acid derivative has a structure as shown in a formula I. The glutamic acid derivative provided by the invention can up-regulate expression of CLOCK protein and Per3 protein, can inhibit ROS in cells and up-regulate expression of Nrf2, and can be applied to relieving skin problems caused by disorder of circadian rhythm. # imgabs0 #
Owner:HUNAN YUJIA COSMETICS MFG CO LTD

Application of CD132 in treatment of AML

The invention discloses an application of CD132 in treatment of AML (acute myeloid leukemia). The CD132 is differentially expressed in the AML, the expression level of the CD132 is related to the malignant degree of the AML and the total survival rate of AML patients, and CD132 knock-down can inhibit the proliferation capacity of AML cells, influence the cell cycle of the AML cells and promote cell apoptosis of the AML cells.
Owner:PEOPLES HOSPITAL PEKING UNIV

Oral flora marker related to tongue squamous cell carcinoma and application thereof

The invention belongs to the field of biological medicine, and discloses an oral flora marker related to tongue squamous cell carcinoma (TSCC) and application of the oral flora marker. The oral cavity flora marker is Stomatobacterium longum (SBL), and the oral cavity flora marker is SBL (Stomatobacterium longum); the invention further discloses a diagnostic product of the TSCC, application of the SBL in preparation of a medicine for treating the TSCC and the medicine for treating the TSCC. The diagnosis product prepared by taking the SBL as the marker can quickly and effectively carry out early diagnosis on the TSCC so as to achieve the purposes of early discovery, early treatment and improvement of the survival rate. The medicine provided by the invention can specifically inhibit the SBL from secreting the nano extracellular vesicles so as to inhibit the expression of BRCA1 and further inhibit the expression of EXO1 and TP53BP1, so that the proliferation and cell cycle progress of TSCC cells are inhibited, and the treatment on the TSCC is realized. The medicine has good specificity and can be used for effectively treating TSCC.
Owner:EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV (SHENZHEN FUTIAN) +1

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Nucleic acid molecule for inhibiting expression of F11 gene

The present invention relates to a nucleic acid molecule for inhibiting FXI gene expression through RNAi, and more particularly, to a nucleic acid molecule for inhibiting FXI gene expression through RNAi, the nucleic acid molecule comprises a sense sequence and an antisense sequence which are complementary to each other or is composed of a sense sequence and an antisense sequence which are complementary to each other, and the FXI inhibition rate of the nucleic acid molecule is significantly superior to that of other small nucleic acid molecules for inhibiting FXI expression through RNAi.
Owner:CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD

Neutralizing nucleic acid aptamer for targeted inhibition of B cell activating factor and application of neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

SiRNA for inhibiting expression of apolipoprotein C3

PendingCN119421952AMetabolism disorderDNA/RNA fragmentationDiseaseApolipoprotein C3
A siRNA that inhibits the expression of apolipoprotein C3 is provided. Provided are a small interfering RNA (siRNA) for inhibiting expression of APOC3 in a cell, a vector and a cell comprising a nucleotide encoding the same, and a method for treating a disease or symptom associated with expression of APOC3 in a subject using the siRNA, the vector or the cell.
Owner:SHANGHAI RONA THERAPEUTICS CO LTD

Use of GPR1 as target in preparing endometriosis-related diagnostic and / or therapeutic formulation

PCT designated stage expiredWO2025076775A1Microbiological testing/measurementDeep infiltrating endometriosisOvarian Endometriosis
A use of a GPR1 as a target in preparing an endometriosis-related diagnostic and / or therapeutic formulation, relating to the technical field of biomedicine. The present invention provides a use of a GPR1 target as a diagnostic marker in preparing a reagent or kit for diagnosing endometriosis. The endometriosis is selected from one of uterosacral ligament endometriosis, peritoneal endometriosis, rectovaginal endometriosis, deep infiltrating endometriosis, and ovarian endometriosis. The present invention discovers that the expression of the GPR1 is significantly increased in endometriosis tissues and cells, indicating that the GPR1 can be used as a diagnostic marker for endometriosis. It has been discovered in in-vitro and in-vivo models that GPR1 knockout significantly inhibits the abilities of hEM15A cells to proliferate, migrate, and invade and the growth of ectopic foci in animals, indicating that the GPR1 can be used as a new intervention target for clinically treating endometriosis.
Owner:SHENZHEN INST OF ADVANCED TECH

Polypeptide with whitening effect as well as preparation method and application thereof

The invention discloses a polypeptide with a whitening effect and a preparation method and application thereof.The polypeptide is obtained from hydrolyzed protein of babylonia areolata, the amino acid sequence of the polypeptide is cysteine-arginine-proline-threonine-cysteine-serine-arginine-leucine-alanine-cysteine, and the amino acid sequence of the polypeptide is cysteine-arginine-proline-threonine-cysteine-serine-arginine-leucine-alanine. The compound can obviously inhibit the generation of melanin in cells and the activity of tyrosinase in vitro, has the characteristics of low toxicity, low irritation, good stability, safety and high efficiency, and can be applied to whitening cosmetics.
Owner:PROYA COSMETICS CO LTD

Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)

The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and / or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and / or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and / or TAM. The methods and compositions are useful for treating a disease associated with MDSC and / or TAM infiltration into a tissue or tumor.
Owner:IMMUNITYBIO INC

Man-PFH-ICG (at) PLGA nanoparticles as well as preparation method and application thereof

The invention discloses Man-PFH-ICG (at) PLGA nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of composite material preparation. According to the invention, PLGA is used as a carrier, the surface of the PLGA is marked with mannose by using polylactic acid-glycolic acid (PLGA) nanoparticles (NPs), and ICG and oxygen-carrying PFH are embedded in the PLGA nanoparticles, so that the obtained Man-PFH-ICG-PLGA nanoparticles have an excellent targeting effect on a mannose receptor overexpressed on the surface of a tumor cell, and obviously promote effective endocytosis of the cell and tumor enrichment in vivo in vitro; the hypoxic environment of tumors is directly relieved; in addition, oxygen can be supplemented endogenously, ROS generated by cells is used for activating TRPA1 channels over-expressed on the surfaces of tumor cells, and therefore cell respiration is inhibited, oxygen consumption is reduced, the tumor hypoxia environment is indirectly relieved, tumor cell growth is effectively inhibited, and a new thought is added for clinical exploration of anti-tumor treatment.
Owner:CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

Methods for selecting a cancer patient for immunotherapy comprise establishing a total passenger gene mutation burden from a tumor of a cancer patient, generating a background distribution for the mutational burden of the tumor, normalizing the total passenger gene mutation burden against the background distribution, and categorizing the cancer patient as an immunotherapy responder when the total passenger gene mutation burden is greater than the mean of the background distribution. When the cancer patient is an immunotherapy responder, the patient may be administered an immunotherapy regimen that comprises activation / inhibition of T cell receptors that promote T cell activation and / or prolong immune cytolytic activities.
Owner:REGENERON PHARMACEUTICALS INC

Methods of modulating immune responses with cationic lipid vaccine compositions

The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +1

Application of anti-IGF-1R antibody or antigen binding part thereof in weight loss

The invention belongs to the field of biological medicine, and particularly relates to application of an anti-IGF-1R antibody or an antigen binding part thereof in weight loss. The invention provides an application of an anti-IGF-1R antibody or an antigen binding part thereof in weight loss. The anti-IGF-1R antibody or the antigen-binding portion thereof is reduced in weight by at least one of the following mechanisms: (1) inhibiting or blocking the binding between IGF-1R and IGF-1; (2) the activity of IGF-1R is reduced, weakened or neutralized; (3) inhibiting cell proliferation; (4) inhibiting fat synthesis and / or accumulation of cells; and (5) inhibiting collagen synthesis of cells. The anti-IGF-1R antibody or the antigen binding part thereof can significantly inhibit the generation and accumulation of fat and effectively inhibit the formation of collagen, and has a significant effect in the treatment of obesity and weight loss.
Owner:SUZHOU PRO HEAL PHARM TECH CO LTD

CFB inhibitor composition and use thereof

PCT designated stage expiredWO2025026228A1Organic active ingredientsSpecial deliveryDiseaseNucleotide
The present invention relates to the technical field of nucleic acid drugs, and particularly provides a double-stranded oligonucleotide for inhibiting complement factor B (CFB) gene expression. The double-stranded oligonucleotide comprises a sense strand and an antisense strand; the sense strand contains at least fifteen consecutive nucleotides in any one sequence shown as SEQ ID NO: 1-SEQ ID NO: 255 in Table 1 or a nucleotide sequence which differs from the at least fifteen consecutive nucleotides in respect of not more than three nucleotides; and / or, the antisense strand contains at least fifteen consecutive nucleotides in any one sequence shown as SEQ ID NO: 256-SEQ ID NO: 510 in Table 1 or a nucleotide sequence which differs from the at least fifteen consecutive nucleotides in respect of not more than three nucleotides. The double-stranded oligonucleotide can inhibit CFB gene expression in cells, thereby achieving the effects of relieving, treating and / or preventing diseases or disorders mediated by abnormal CFB gene expression.
Owner:RIGERNA THERAPEUTICS (SUZHOU) CO LTD

Application of SAAL1 as prognosis evaluation marker and drug target of neuroblastoma

The invention belongs to the technical field of biological medicine, and particularly relates to application of SAAL1 as a prognosis evaluation marker and a drug target of neuroblastoma. The invention provides a series of applications of SAAL1 as a neuroblastoma drug target, including prognosis, treatment and other aspects of neuroblastoma. The invention proves that the NB tumor staging and risk level grading of the high-expression SAAL1 gene are high, the survival time of a child patient is short, and the SAAL1 gene can be used as a neuroblastoma prognosis molecule. In a human neuroblastoma cell line, cell proliferation can be inhibited by knocking down the SAAL1, which indicates that the SAAL1 can be used as a therapeutic target of the neuroblastoma. According to the invention, NB risk level grading can be realized from a molecular level, NB treatment can be realized by targeting the SAAL1 gene, and clinical doctors can be assisted in prognosis judgment and targeted treatment of NB.
Owner:BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Gout biomarker HIF-1alpha and application thereof

The invention relates to the field of biological medicine, in particular to application of a reagent for measuring or regulating the expression level of HIF-1alpha in preparation of a kit for diagnosing or gout, the kit containing the reagent and a gout prediction device. The HIF-1alpha is applied as a gout diagnosis target and a treatment target for the first time, the polarization degree of Th17 cells in an inflammatory microenvironment of a gout patient can be specifically reflected, early dynamic monitoring of gout related inflammatory activities is achieved, polarization of Th17 cells and expression of related proinflammatory factors are inhibited in a targeted mode, and a new strategy is provided for prediction, diagnosis and treatment of gout.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Compositions and methods for suppressing intracellular synthesis of the beta subunit of human chorionic gonadotropin

ActiveUS12590308B1Organic active ingredientsTumor/cancer cellsBase JHCG - Human chorionic gonadotropin
A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.
Owner:JAMES SUMMERTON LIVING TRUST DATED MAY 15 2008